ESMO 2023 BioNTech Data slide image

ESMO 2023 BioNTech Data

All patients had received anti-PD1 and anti-CTLA-4 therapy • Patients had received a median of 3 prior therapies BNT221 in Heavily Pretreated Melanoma Patients Phase 1 FIH study (NCT04625205): Baseline characteristics. Borgers J. et al. Presented at ESMO 2023. Abstract #10170. Baseline patient characteristics Median age (range) Sex M/F, n (%) ECOG 0-1, n (%) Stage IV at entry, n (%) Serum LDH increased, n (%) Tumor Burden at Prescreen median sum of TL, range (mm) Prior lines of systemic therapy median (min/max) Prior aPD-1 therapy, n (%) Total (n=9) 57 (32-72) 2 (22%) 7 (78%) 9 (100%) 9 (100%) 1 (11%) 44 (16-177) 3 (2/4) 9 (100%) 6 (67%) 4 (44%) 1 (11%) 9 (100%) 2 (22%) 2 (22%) Adjuvant Metastatic Both Prior aCTLA-4 therapy, n (%) Prior BRAF/MEK-directed therapy, n (%) Other, n (%) BRAF: V-Raf Murine Sarcoma Viral Oncogene Homolog B; ECOG: Eastern Cooperative Oncology Group; F: female, LDH: lactate dehydrogenase; M: male,; MEK: Mitogen-activated protein kinase kinase; TL: target lesion. 23 BIONTECH
View entire presentation